PREM14C EX-FILING FEES 0001894525 0-11 N/A 0001894525 1 2026-01-15 2026-01-15 0001894525 2026-01-15 2026-01-15 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

SC 14C

Apimeds Pharmaceuticals US, Inc.

Table 1 to Paragraph (a)(7)

Line Item Type |  | Notes |  | Transaction Valuation |  | Fee Rate |  | Amount of Filing Fee
Fees to be Paid |  | (1) |  | $ | 26,647,462.00 |  | 0.0001381 |  | $ | 3,680.01
Total Transaction Valuation: |  | $ | 26,647,462.00 |  |  |  |  |
Total Fees Due for Filing: |  |  |  |  |  |  | $ | 3,680.01
Total Fees Previously Paid: |  |  |  |  |  |  |  | 0.00
Total Fee Offsets: |  |  |  |  |  |  |  | 0.00
Net Fee Due: |  |  |  |  |  |  | $ | 3,680.01

__________________________________________
Offering Note(s)

(1) |  | Based on the 14,970,484 shares of APUS common stock outstanding at the closing of the Merger Agreement and the quoted market price of $1.78 per share, the total purchase consideration is $26,647,462. The filing fee was calculated in accordance with 17 CFR § 240.0-11(c)(1) by multiplying the transaction valuation by the fee rate.